David G. Kirsch

David G. Kirsch

Auto-generated profile, based on publicly available information

David G. Kirsch

Department of Radiation Oncology, Duke University , Durham, NC

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
EMEverett J. Moding
Everett J. Moding
MKMichael B. Kastan
Michael B. Kastan
DKDavid G. Kirsch
David G. Kirsch

6 January 2016 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MWMelodi Javid Whitley
Melodi Javid Whitley
DCDiana M. Cardona
Diana M. Cardona
ALAlexander Lazarides
Alexander Lazarides
ISIvan Spasojevic
Ivan Spasojevic
JFJorge M. Ferrer
Jorge M. Ferrer
BBBrian E. Brigman
Brian E. Brigman
A first-in-human phase 1 clinical trial of the PEGylated protease-activated fluorescent probe, LUM015, enables tumor imaging at a safe and tolerable dose in humans.

28 April 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
AFAnna Maria Frezza
Anna Maria Frezza
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
EBElizabeth H. Baldini
Elizabeth H. Baldini
SBSylvie Bonvalot
Sylvie Bonvalot
ATAnnalisa Trama
Annalisa Trama

29 April 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
KKKyu-Tae Kim
Kyu-Tae Kim
HLHye Won Lee
Hye Won Lee
Hae-Ock LeeHae-Ock Lee
Hae-Ock Lee
HSHye Jin Song
Hye Jin Song
DJDa Eun Jeong
Da Eun Jeong
WPWoong-Yang Park
Woong-Yang Park
Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy. Using single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platforms in vitro and in vivo. Our findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.

22 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
PAPierre-Benoit Ancey
Pierre-Benoit Ancey
CCCaroline Contat
Caroline Contat
GBGael Boivin
Gael Boivin
SSSilvia Sabatino
Silvia Sabatino
JPJustine Pascual
Justine Pascual
EMEtienne Meylan
Etienne Meylan
Neutrophils are the most abundant circulating leucocytes and are essential for innate immunity. In cancer, pro- or antitumor properties have been attributed to tumor-associated neutrophils (TAN). Here, focusing on TAN accumulation within lung tumors, we identify GLUT1 as an essential glucose transporter for their tumor supportive behavior. Compared with normal neutrophils, GLUT1 and glucose metabolism increased in TANs from a mouse model of lung adenocarcinoma. To elucidate the impact of glucose uptake on TANs, we used a strategy with two recombinases, dissociating tumor initiation from neutrophil-specific Glut1 deletion. Loss of GLUT1 accelerated neutrophil turnover in tumors and reduced a subset of TANs expressing SiglecF. In the absence of GLUT1 expression by TANs, tumor growth was diminished and the efficacy of radiotherapy was augmented. Our results demonstrate the importance of GLUT1 in TANs, which may affect their pro- versus antitumor behavior. These results also suggest targeting metabolic vulnerabilities to favor antitumor neutrophils.Significance: Lung tumor support and radiotherapy resistance depend on GLUT1-mediated glucose uptake in tumor-associated neutrophils, indicating that metabolic vulnerabilities should be considered to target both tumor cells as well as innate immune cells.

28 August 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AWAmy J. Wisdom
Amy J. Wisdom
CHCierra S. Hong
Cierra S. Hong
ALAlexander J. Lin
Alexander J. Lin
YXYu Xiang
Yu Xiang
DCDaniel E. Cooper
Daniel E. Cooper
DKDavid G. Kirsch
David G. Kirsch
Nearly two-thirds of cancer patients are treated with radiation therapy (RT), often with the intent to achieve complete and permanent tumor regression (local control). RT is the primary treatment modality used to achieve local control for many malignancies, including locally advanced cervical cancer, head and neck cancer, and lung cancer. The addition of concurrent platinum-based radiosensitizing chemotherapy improves local control and patient survival. Enhanced outcomes with concurrent chemoradiotherapy may result from increased direct killing of tumor cells and effects on nontumor cell populations. Many patients treated with concurrent chemoradiotherapy exhibit a decline in neutrophil count, but the effects of neutrophils on radiation therapy are controversial. To investigate the clinical significance of neutrophils in the response to RT, we examined patient outcomes and circulating neutrophil counts in cervical cancer patients treated with definitive chemoradiation. Although pretreatment neutrophil count did not correlate with outcome, lower absolute neutrophil count after starting concurrent chemoradiotherapy was associated with higher rates of local control, metastasis-free survival, and overall survival. To define the role of neutrophils in tumor response to RT, we used genetic and pharmacological approaches to deplete neutrophils in an autochthonous mouse model of soft tissue sarcoma. Neutrophil depletion prior to image-guided focal irradiation improved tumor response to RT. Our results indicate that neutrophils promote resistance to radiation therapy. The efficacy of chemoradiotherapy may depend on the impact of treatment on peripheral neutrophil count, which has the potential to serve as an inexpensive and widely available biomarker.